April 3, 2017
Verona Pharma in managerial changes
Verona Pharma’s non-executive director Patrick Humphrey has decided to retire from the Board, effective April 15, 2017. The company said it doesn’t plan replacing him.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Verona Pharma
March 22, 2017
Verona Pharma and QuintilesIMS in strategic agreement to develop respiratory drugs
Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, has entered into a global strategic services agreement with QuintilesIMS, a provider of biopharmaceutical development and commercial outsourcing services.
February 27, 2017
Verona puts COPD candidate RPL544 in focus for 2017, NASDAQ in four months?
According to Verona Pharma’s CEO, Dr. Jan-Anders Karlsson, the highlights of 2016 were encouraging clinical data for RPL554, additional financing from “a very experienced syndicate” of investors, and further strengthening of the company’s Board and executive team.
February 22, 2017
Verona kicks off phase two for its COPD candidate RPL544 as add-on to Spiriva
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
February 13, 2017
Verona Pharma 10million newly consolidate ordinary shares
Verona Pharma said on Monday that, after the 50 for 1 share consolidation approved by shareholders on 8 February 2017, it now has 51,361,064 ordinary shares of £0.05 each in issue, each carrying one voting right.
September 12, 2016
New Board member to Verona Pharma
Verona Pharma #VRP appoints Vikas Sinha to the Board as a Non-Executive Director
March 22, 2016
Verona Pharma: “A successful year with significant progress”
Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, has provided a summary review of its 2015 performance.
March 15, 2016
Verona Pharma reports positive results from RPL554 dose-finding study
Verona Pharma reports positive results from RPL554 dose-finding study
November 5, 2015
Verona Pharma completes inhibitor study
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.
October 14, 2015
Verona Pharma: Start of RPL554 Phase IIa combination study
Verona Pharma plc , the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).